Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Feb 23, 2010


Stephen Lombardi has left his job as president of Helicos BioSciences, and current CEO Ronald Lowy will take over the position, the company said in a recent filing with the US Securities and Exchange Commission.

Lombardi, who also has resigned from the firm's board of directors, will receive the amount of his gross annual salary of $375,000 in severance, plus stock options. Prior to joining Helicos, Lombardi had served as senior vice president at Affymetrix. Lowy has been CEO of Helicos since late 2007, and before that he was CEO and president of Fisher Biosciences, part of Thermo Fisher Scientific.

The Human Genome Organization has re-elected its president Edison Liu. Liu is executive director of the Genome Institute of Singapore and he has been HUGO's president since 2007.

Martin Schneider is now chair of the advisory board of imaGenes, the Berlin-based genomics services company said last week. Schneider replaces Klaus Schmidt-Menschner, who left to pursue other interests. Schneider is head of global therapeutic research at Bayer Schering Pharma. He was previously head of global target discovery and biomarkers at Bayer. Before that, he was head of enabling technologies at Schering.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.